Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

被引：9

作者：

Jazieh, A. R. ^{[1
,2
]}

Komrokji, R. ^{[1
]}

Gupta, A. ^{[1
]}

Patil, S. ^{[3
]}

Flora, D. ^{[4
]}

Knapp, M. ^{[5
]}

Issa, M. ^{[2
]}

Karim, N. Abdel ^{[1
]}

机构：

[1] Univ Cincinnati, Cincinnati, OH USA

[2] King Abdul Aziz Med City, Riyadh, Saudi Arabia

[3] Univ Memphis, Memphis, TN 38152 USA

[4] Oncol Hematol Oncol Care, Cincinnati, OH USA

[5] Mid Ohio Hematol Oncol, Columbus, OH USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 09期

关键词：

Thalidomide; non small cell lung cancer; chemotherapy; angiogenesis inhibitor; SOLID TUMORS; CHEMOTHERAPY; ANGIOGENESIS; COMBINATION; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PLATINUM; FUTURE;

D O I：

10.3109/07357900801944856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000 mg/m(2) day 1 & 8 and Irinotecan 100 mg/m(2) day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10%) experienced partial response and 14 (70%) experienced stable disease. The median time to disease progression was 4 months (95% CI: 2.8-6.6). The 1 year and 2 year survival rates were 36% and 27%, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

引用

页码：932 / 936

页数：5

共 22 条

[1] Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation [J].

Allegrini, Giacomo ;

Di Paolo, Antonello ;

Cerri, Elisa ;

Cupini, Samanta ;

Amatori, Federica ;

Masi, Gianluca ;

Danesi, Romano ;

Marcucci, Lorenzo ;

Bocci, Guido ;

Del Tacca, Mario ;

Falcone, Alfredo .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (05) :585-593

[2]

Bengtson EM, 1999, SEMIN ONCOL, V26, P1

[3]

Comis RL, 1999, SEMIN ONCOL, V26, P14

[4] The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines:: possible involvement in the PPARγ pathway [J].

DeCicco, KL ;

Tanaka, T ;

Andreola, F ;

De Luca, LM .

CARCINOGENESIS, 2004, 25 (10) :1805-1812

[5]

Dragnev KH, 1999, SEMIN ONCOL, V26, P73

[6] Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis [J].

Du, GJ ;

Lin, HH ;

Xu, QT ;

Wang, MW .

VASCULAR PHARMACOLOGY, 2005, 43 (02) :112-119

[7] Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? [J].

Ferrigno, D ;

Buccheri, G .

LUNG CANCER, 2000, 29 (02) :91-104

[8] Effects of thalidomide on parameters involved in angiogenesis:: an in vitro study [J].

Gelati, M ;

Corsini, E ;

Frigerio, S ;

Pollo, B ;

Broggi, G ;

Croci, D ;

Silvani, A ;

Boiardi, A ;

Salmaggi, A .

JOURNAL OF NEURO-ONCOLOGY, 2003, 64 (03) :193-201

[9] Effect of thalidomide on gastrointestinal toxic effects of irinotecan [J].

Govindarajan, R ;

Heaton, KM ;

Broadwater, R ;

Zeitlin, A ;

Lang, NP ;

Hauer-Jensen, M .

LANCET, 2000, 356 (9229) :566-567

[10]

Govindarajan R, 2000, ONCOLOGY-NY, V14, P29

← 1 2 3 →